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Survival and outcomes of surgical treatment of the elderly NSCLC 
in China: a retrospective matched cohort study
Fan, Jiang; Jiang, Ge-Ning; Zu, Xing-Wang; Ding, Jia-An 
Shanghai Pulmonary Hospital, Shanghai, China
Aim: To compare survival and outcomes of pulmonary resection for 
elderly NSCLC patients with that of younger controls in China.
Methods: A database which included 4,792 NSCLC patients who 
received complete surgery from 1985 to 2005 was used. The elderly pa-
tients (≥70) were matched 1:1 to controls (<70) by 5 variables: gender; 
stage; histology; pulmonary resection types; adjuvant chemotherapy. 
The long-term survival rates, the operative mortality and short-term 
death after surgery were compared. 
Results: There were 1304 patients: 652 cases were ≥70. The 5-year OS 
of elderly was 39.41%; the controls was 44.98 %( p=0.056). Opera-
tive mortality rate between elderly and the controls was similar (9/652 
Vs 4/652 p=0.163) but the short-term death within 2 months after the 
surgeries were different (23/652 Vs 7/652 p=0.003). The elderly with 
lobectomy had a worse 5-year OS than controls (42.47%. Vs 46.47% 
p=0.0476), but the 5-year OS is similar for patients who received 
pneumonectomy (24.12% Vs 35.61% p=0.3960) and the limited resec-
tions (45.82% Vs 39.25% p=0.2735). The OS in patients who received 
adjuvant chemotherapy were similar (49.40%. Vs 43.89% p=0.0955). 
Conclusion: Elderly have the similar long-term OS with the controls. 
They should not be denied the curative surgery and adjuvant chemo-
therapy based on their chronologic age. However, elderly patients had 
a higher risk of short-term death after the surgery, which suggests that 
elderly be given more intensive care after the surgery. 
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Long-term prognosis of sublobar resection for lung cancer in high-
risk patients
Furutachi, Akira; Sakuragi, Tohru; Mitsuoka, Masahiro; Itoh, Tsuyoshi 
Thoracic and Cardiovascular Surgery, Saga University, Saga, Japan
Background: The selection of segmentectomy or wedge resection in 
the treatment of high-risk lung cancer patient remains controversial. We 
compared these two procedures with respect to long-term survival over 
a period of 12 years. 
Methods: Between January 1994 and December 2005, we performed 
a surgical operation in 544 patients with a primary lung cancer. We re-
viewed 47 patients who underwent sublobar resection (segmentectomy 
or wedge resection) for age, sex, comobidities, type of resection, tumor 
size, pathology, clinical stage, body surface area (BSA), pulmonary 
function, operation time, intraoperative bleeding and recurrence. (No-
guchi classiﬁcation A and B were excluded). 
Results: A total of 20 patients underwent segmentectomy (S group), 
and 27 underwent wedge resection (W group). All cases had the risk 
factors such as cardiac disease, impaired pulmonary function, cerebro-
vascular disease, or high age, etc. The average age was 71.0±9.3 years 
old and there were 38 male, and 9 females. The clinical stages were: 
39 stage I, 2 stage II and 5 stage III. The average follow-up period was 
1288.7±807.0 days, and the overall 5-yr survival rate was 63.8%. In 
univariate analysis, the W group had a signiﬁcantly shorter operation 
time (260.±63.3 vs. 120.2±41.0 min; p<0.0001), and less intraoperative 
bleeding (171.2±36.4 vs. 70.5±22.4 ml; p=0.018). There were not sig-
niﬁcant differences in age, BSA, FVC%, FEV1.0%, PaO2, PaCO2, and 
tumor size between the two groups. Local recurrence was recognized 
in 2 patients (10%) in the S group, and 2 (7.4%) in the W group. There 
were no differences in recurrence-free survival (58% vs. 31%;p=0.291) 
or the 5-yr survival rate (61% vs. 63%; p=0.959) between two groups. 
Conclusions: There was no difference in long-term results between 
segmentectomy and wedge resection in high-risk patients that under-
went lung cancer surgery. Wedge resection could be considered an 
alternative procedure in high-risk patients with non-small cell lung 
cancer. Randomized trials are necessary to conﬁrm these results. 
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Organ-conserve surgery in case of advance and regional spread 
lung cancer
Gagua, Rezo; Kuchava, Vladimer; Giorgadze, David; Lomidze, Zaza 
National Cancer Centre, Tbilisi, Georgia
During of 20 year period at the department of thoracic surgery of 
National Cancer Centre of Tbilisi, Georgia had done 678 the wide and 
combined lung resection. The main reason of distending range of sur-
gery was direct invasion of tumor into different intrathoracic structure 
and/or metastatic damage of mediastinal lymph nodes. 
The wide and combine lob-bilobectomy and other partial resections 
with plastic of bronchies had done in 225 cases, from them lobectomy 
with whole mediastinal limphadenectomy in 66 cases, the combined 
lobectomy with other intrathoracic organs and anatomic structures in 
57 cases. 
Combination of these two types of resection in case of tumor invasion 
with mediastinus lymph node damage had done in 39 cases. The differ-
ent types of pneumonectomy had done in 453 cases. From above men-
tioned cases wide pneumonectomy had done in 155 cases, combined 
- in 138 cases, wide-combined in 129 cases. In 31 cases, when tumor 
was spreaded at proximal part of main bronchi, had done side resection 
of trachea at tracheobronchial angle, or resection of bifurcation. 
Despite of wide surgery and combinative lob-bilobectomy, there is not 
deﬁne with signiﬁcant improvement of post operative complications 
and mortality. 
After wide resection post operative complications was noted in 11.7% 
cases, after plastic surgery - in 12.7% cases, and post typical lob-bi-
lobectomy - in 10.1% cases and correspondingly mortality comes to 
6.2%, 7.9% and 5.1% of cases. 
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Significant morbidity without mortality following neoadjuvant 
chemo/chemoradiation therapy in patients undergoing lung 
resection for NSCLC
Bayram, Ahmet S.1 Köprücüoğlu, Mustafa1 Kanat, Özkan2 Saruhan, 
Süreyya3 Evrensel, Türkkan2 Mehmet, Karadağ4 Gebitekin, Cengiz1 
1 Department of Thoracic Surgery, Medical Faculty of Uludag Univer-
sity, Bursa, Turkey 2 Department of Medical Oncology, Medical Faculty 
of Uludag University, Bursa, Turkey 3 Department of Radiation Oncol-
ogy, Medical Faculty of Uludag University, Bursa, Turkey 4 Department 
of Chest Disease, Medical Faculty of Uludag University, Bursa, Turkey 
Neoadjuvant therapy has become an accepted treatment for locally 
advanced lung cancer however, lung resections following neoadjuvant 
chemo/chemoradiation therapy carry higher risk of morbidity and mor-
Copyright © 2007 by the International Association for the Study of Lung Cancer S773
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
tality particularly in patients undergoing pneumonectomy. We reviewed 
our experience to deﬁne it further.
Patients with locally advanced Non-small cell lung cancer (NSCLC) 
lung cancer undergoing induction therapy were prospectively reviewed. 
Chemotherapy, 2-6 cycles, or chemoradiation, 40-45 Gy with two 
agents chemotherapy, was given and the surgery was performed at least 
3 weeks after the treatment. All complications, hospital mortality, if oc-
curred, and hospital stay were recorded and the patients were followed-
up with 3 months interval. 
One hundred and eight patients were included in the study. All but six 
patients were male with a mean age of 58.9 years. Squamous cell carci-
noma is the dominant cell type and was observed in 63 (58%) patients. 
Mediastinoscopy was performed in 47 (44%) patients. Lobectomy 
was the most common resection and performed in 66 (61%) patients, 
pneumonectomy in 19 (18%) patients, lesser resections in 11 (10%) 
and exploratris thoracotomy in 12 (11%) patients. Although mortality 
was not observed, major morbidity was observed in 33 (31%) patients. 
The most common complication was pneumonia or empyema that was 
seen in 11 patients (33%) patients. The morbidity rate was 39% in total 
of 288 patients and the difference was statistically was not signiﬁcant, 
p>0.05. 
Induction therapy for NSCLC is an effective for down-staging of the 
tumor however it was associated with signiﬁcant morbidity in our 
series. Mortality could be avoided in highly selective patients.
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Pulmonary function tests as a predictor of quantitative and 
qualitative outcomes after thoracic surgery for lung cancer
Greillier, Laurent1 Thomas, Pascal A.1 Loundou, Anderson2 Doddoli, 
Christophe1 Barrau, Karine2 Badier, Monique1 Auquier, Pascal2 Barlesi, 
Fabrice1 
1 Faculty of Medicine (Universite de la Mediterranee) - Assistance Pub-
lique Hopitaux de Marseille, Marseille, France 2 Faculty of Medicine 
(Universite de la Mediterranee), Marseille, France 
Background: Pulmonary function tests (PFT) are used to select non-
small cell lung cancer (NSCLC) patients suitable for thoracic surgery. 
The present study aimed to explore the impact of PFT on both quantita-
tive (morbidity, mortality, overall survival) and qualitative (quality 
of life-QOL) outcomes of patients undergoing thoracic surgery for 
NSCLC.
Methods: Patients with proven or highly probable NSCLC referred for 
thoracic surgery were eligible. Postoperative outcomes as morbidity, 
90-day mortality, QOL based on the Psychological Global Well Being 
Index (PGWBI) and on the European Organization for Research and 
Treatment of Cancer quality of life Questionnaire (EORTC QLQ-
C30), and overall survival were studied according to the results of the 
preoperative PFT (forced expiratory volume in one second, FEV1; vital 
capacity, VC; residual volume, RV; total lung capacity, TLC; airways 
resistance, RAW; diffusing capacity corrected for alveolar volume, 
DLCO/VA).
Results: A total of 110 patients were studied with 94 patients eligible 
for analysis. Postoperative mortality and morbidity affected 9.5 and 
40% of patients, respectively. These patients presented with signiﬁ-
cantly lower preoperative values of VC, TLC and DLCO/VA and 
higher preoperative values of RAW when compared with patients with 
an uncomplicated postoperative course (Table I). A better survival was 
correlated with higher preoperative values of FEV1, VC and TLC and a 
lower pulmonary distension, especially when expressed as a percentage 
of predicted value (Table II). None of the postoperative QOL scores 
was inﬂuenced by preoperative PFT results.












FEV1 (L) 2.6 ± 0.8 2.4 ± 0.8 0.2 (-0.7 - 0.6) 0.12
FEV1 (% pred) 91 ± 21 83 ± 23 8 (-1.7 - 17.3) 0.11
VC (L) 3.9 ± 0.9 3.4 ± 1.1 0.5 (0.1 - 0.9) 0.02
VC (% pred) 101.3 ± 17.9 89.6 ± 19.3 11.7 (3.7 - 19.8) <0.01
TLC (L) 6.8 ± 1.1 6.2 +/- 1.5 0.6 (-0.1 - 1.3) 0.09
TLC (% pred) 106.5 ± 14.7 96.5 ± 18 10 (1.3 - 18.6) 0.02
RV/TLC (%) 39.1 ± 9.6 43.3 +/- 9.7 -4.2 (-9 - 0.5) 0.08
RV/TLC (% pred) 108.7 ± 25.5 113.8 ± 26.6 -5.1 (-18.8 - 8.6) 0.46
RAW (cmH20/L/s) 1.8 ± 0.6 2.5 ± 1.3 -0.7 (-1.3 -0.1) 0.02
RAW (% pred) 69.2 ± 35.6 91 ± 47.1 -21.8 (-45.9 - 2.3) 0.05
DLCO/VA (mL/
min/mmHg/L) 3.6 ± 0.7 3 ± 0.9 0.6 (-0.1 - 1.1) 0.02
DLCO/VA (%pred) 75.2 ± 15.8 65.2 ± 17.6 10 (1.5 - 18.5) 0.05
*Results presented as mean ± SD (range)
Abbreviations:  
CI, conﬁdence interval; FEV1, forced expiratory volume in one second;  
% pred, percentage of the predictive value; VC, vital capacity;  
TLC, total lung capacity;  
RV, residual volume; RAW, airways resistance;  
DLCO/VA, diﬀusing capacity corrected for alveolar volume.
Table II: Comparison of pulmonary functional parameters according to 
overall survival (n=94)




FEV1 (L) 2.6 ± 0.8 2.2 ± 0.7 0.4 (-0.5 - 0.9) 0.08
FEV1 (% pred) 89.4 ± 22 76.2 ± 16.7 13.2 (-0.7 - 26.6) 0.05
VC (L) 3.7 ± 1 3.1 ± 0.8 0.6 (0.1 - 1.2) 0.06
VC (% pred) 97.7 ± 19.9 84.1 ± 9.4 13.6 (2 - 25.3) 0.02
TLC (L) 6.6 ± 1.3 5.4 ± 1.4 1.2 (-0.4 - 2.1) <0.01
TLC (% pred) 104 ± 15.5 86 ± 19 18 (5.8 - 30.1) <0.01
RV/TLC (%) 40.2 ± 9.3 48.5 ± 10.7 -8.3 (-15 - -1.5) 0.02
RV/TLC (% pred) 107.7 ± 24.6 132.8 ± 24.8 -25.1 (-43.8 - 6.2) 0.01
RAW (cmH20/L/s) 2.1 ± 1.1 2.7 ± 0.9 -0.6 (-1.4 - -0.3) 0.20
RAW (% pred) 76.4 ± 41.7 100.4 ± 45.9 -24 (-56.9 - 9) 0.12
DLCO/VA (mL/
min/mmHg/L) 3.4 ± 1.1 3.3 ± 0.9 0.1 (-0.6 - 0.8) 0.69
DLCO/VA (%pred) 73.2 ± 17.6 69.4 ± 18 3.8 (-22.8 - 31.2) 0.62
*Results presented as mean ± SD (range)
Abbreviations:  
CI, conﬁdence interval;  
FEV1, forced expiratory volume in one second;  
% pred, percentage of the predictive value;  
VC, vital capacity; TLC, total lung capacity;  
RV, residual volume; RAW, airways resistance;  
DLCO/VA, diﬀusing capacity corrected for alveolar volume.
